JIN MEDICAL INTERNATIONAL LTD. Enters into Memorandum of Understanding to Acquire Medical Equipment Sharing Platform
2023年12月14日 - 10:30PM
JIN MEDICAL INTERNATIONAL LTD. (the "Company" or “JinMed”) (NASDAQ:
ZJYL), a Cayman Islands holding company with Chinese operating
entities that manufacture and develop wheelchairs and living aids
products, today announced the signing of a preliminary Memorandum
of Understanding (MOU) with Jiangsu Zhongjin Kanglu Information
Technology Co., Ltd. ("Zhongjin Kanglu") to acquire all or a
partial stake in Zhongjin Kanglu.
According to the MOU, the Company will conduct a
comprehensive due diligence process to evaluate and determine the
feasibility and potential value of the acquisition. It is expected
that the due diligence will be completed by December 31, 2023.
It is expected that commencing from March 2024,
the parties will enter into detailed negotiations for the potential
acquisition. Investors should exercise caution as there is no
certainty that the potential acquisition will be completed.
Zhongjin Kanglu is a company that engages in
medical equipment sharing business, leveraging its manufacturing
expertise and big data analytics technology. This program primarily
caters to individuals with medical care needs, providing
round-the-clock shared medical equipment such as wheelchairs,
emergency carts, and companion beds. The aim is to address
challenges faced by healthcare institutions, such as inadequate
equipment availability, limited service hours, and cumbersome
leasing procedures, thereby significantly enhancing the convenience
for patients seeking medical treatment. Zhongjin Kanglu’s shared
wheelchairs have been adopted by over 1,600 leading hospitals
nationwide in China.
Through equipment rentals, Zhongjin Kanglu
operates a Small-V Sharing Project that generates base income,
while additional revenue is obtained by guiding users to purchase
related equipment and financial service products. To date, the
Small-V Sharing program has expanded to cover all 30 provinces.
Mr. Wang Erqi, Chairman and CEO of the Company,
commented, "The signing of this highly anticipated MOU marks an
important milestone in the collaboration and development between
the Company and Zhongjin Kanglu. As a leading enterprise in the
field of shared medical equipment, with its Small V Sharing
Project, the innovative solutions and well-established channels in
medical institutions brought by it, Zhongjin Kanglu will create a
good synergistic effect for the promotion of JinMed’s products in
China. We intend to proceed with the acquisition process in full
swing while bringing more innovation and growth opportunities to
the industry."
About Jin Medical International
Ltd.
Founded in 2006 and headquartered at Changzhou
City, Jiangsu Province of China, the Company, through its Chinese
operating entities, designs and manufactures wheelchairs and living
aids products for people with disabilities, the elderly, and people
recovering from injuries. The Company’s Chinese operating entities
operate 2 manufacturing plants with approximately 228,257 square
feet in the aggregate in Changzhou City and Taizhou City, Jiangsu
Province, China. The Company’s Chinese operating entities have
established relationships with over 40 distributors in China, and
over 20 in the other regions of the world where it currently sells
the products. The majority of the Company’s wheelchair products,
with more than 30 models, are sold to dealers in Japan and China,
including Nissin Medical Industries Co., Ltd, one of the largest
medical device distributors in Japan. The Company’s Chinese
operating entities continuously deliver innovative wheelchair
designs that are both lightweight and ergonomic each year. For more
information, please visit: http://www.zhjmedical.com.
Forward-Looking Statement
This press release contains forward-looking
statements as defined by the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements
concerning plans, objectives, goals, strategies, future events or
performances, and underlying assumptions and other statements that
are other than statements of historical facts. When the Company
uses words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, it is
making forward-looking statements. Forward-looking statements are
not guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks, including, but not limited to, the
following: the Company's ability to achieve its goals and
strategies, the Company's future business development and plans for
future business development, including its financial conditions and
results of operations, product and service demand and acceptance,
reputation and brand, the impact of competition and pricing,
changes in technology, government regulations, fluctuations in
general economic and business conditions, and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the U.S. Securities
and Exchange Commission ("SEC"). For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, as
well as its current reports on Form 6-K and other filings, all of
which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the
date hereof. There is no certainty that the potential acquisition
mentioned herein will be completed at all, or upon terms favorable
to the Company.
For more information, please
contact:
ir@zhjmedical.com
Jin Medical (NASDAQ:ZJYL)
過去 株価チャート
から 10 2024 まで 11 2024
Jin Medical (NASDAQ:ZJYL)
過去 株価チャート
から 11 2023 まで 11 2024